LIBREXIA-ACS
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
- Investigator
- Carl J Pepine
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
EVOLVE
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic…
- Investigator
- Carl J Pepine
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
Women's Evaluation of Systemic Aging Tenacity [SCORE: MAE-WEST]-Project 2
- Investigator
- Carl J Pepine
- Status
- Accepting Candidates